References
- Venters C, Graham W, Cassidy W. Recombivax-HB: perspectives past, present and future. Expert Rev. Vaccines3, 119–129 (2004).
- RECOMBIVAX HB®, package insert. Merck, NJ, USA.
- Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th edition. Atkinson W, Wolfe S, Hamborsky J (Eds).Public Health Foundation, Washington DC, USA (2011).
- Caulfield MJ, Shi L, Wang S et al. Effect of alternative aluminium adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Human Vacc.3, 139–146 (2007).
- Hansen B, Sokolovska A, HogenEsch H et al. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine25, 6618–6624 (2007).
- Romero Mendez IZ, Shi Y, HogenEsch H et al. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine25, 825–833 (2007).
- Egan PM, Belfast MT, Gimenez JA et al. Relationship between tightness of binding and immunogenicity in an aluminum-containing adjuvant-adsorbed hepatitis B vaccine. Vaccine27, 3175–3180 (2009).
- Hansen B, Belfast M, Soung G et al. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine27, 888–892 (2009).
- Vesikari T, Martin JC, Liss CL et al. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants. Ped. Infect. Dis.30, e109–e113 (2011).
- Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. 18-years follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin. Gastroenterol. Hepatol.2, 941–945 (2004).
- Chen DS. Long-term protection of hepatitis B vaccine: lessons from Alaskan experience after 15 years. Ann. Intern. Med.142, 384–385 (2005).
- But DY, Lai CL, Lim WL et al. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccine without booster dose in children: final report. Vaccine26, 6587–6591 (2008).
- Lu CY, Ni YH, Chiang BL et al. Humoral and cellular immune response to a hepatitis B vaccine booster 15–18 years after neonatal immunization. J. Infect. Dis.197, 1419–1426 (2008).
- McMahon BJ, Dentinger CM, Bruden D et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J. Infect. Dis.200, 1390–1396 (2009).
- Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose.. Clin. Infect. Dis.53, 68–75 (2011).
- Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine18, 6266–6273 (2008).
- Tong NK, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int.68, 2298–2303 (2005).
- Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev. Vaccines6, 133–140 (2007).
- Van Damme P, Minervini G, Liss CL et al. Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults. Human Vacc.5, 92–97 (2009).
- Zanetti AR, Mariano A, Romanò L et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet366, 1379–1384 (2005).